NAS:ASND (Denmark) Also Trade In: Germany
Ascendis Pharma A/S $ 139.13 -1.34 (-0.95%)
Warning! GuruFocus has detected 2 Severe warning signs with ASND. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for ASND (Ascendis Pharma A/S) from 2015 to Jan 20 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Ascendis Pharma A/S stock (ASND) PE ratio as of Jan 20 2020 is 0. More Details
Ascendis Pharma A/S PE Ratio (TTM) Historical Data
View and export this data going back to 2015. Start your Free Trial
Ascendis Pharma A/S PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:HALO NAS:CBPO NAS:PBYI SZSE:300009 NAS:ANAB NAS:FOLD NYSE:EBS SHSE:600161 XBRU:ARGX NAS:ACAD SZSE:002821 XSWX:GALE XSWX:IDIA NAS:CRSP NAS:RARE NAS:IMMU SZSE:002603 NAS:CLVS SZSE:000990 HKSE:00570
Address Tuborg Boulevard 5, Hellerup, DNK, DK-2900
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP etc. It operates mainly in USA, Germany, and Switzerland and derives the majority of its revenue from the US.